valganciclovir 450mg tablets
accord-uk ltd - valganciclovir hydrochloride - oral tablet - 450mg
valganciclovir 450mg tablets
milpharm ltd - valganciclovir hydrochloride - oral tablet - 450mg
valganciclovir 450mg film-coated tablets
mcdermott laboratories ltd., t/a gerard laboratories - valganciclovir - film-coated tablet - 450 milligram(s) - nucleosides and nucleotides excl. reverse transcriptase inhibitors; valganciclovir
valganciclovir hydrochloride tablet film coated
golden state medical supply inc. - valganciclovir hydrochloride (unii: 4p3t9qf9nz) (ganciclovir - unii:p9g3ckz4p5) - valganciclovir 450 mg
valganciclovir juno valganciclovir (as hydrochloride) 450 mg tablet bottle
juno pharmaceuticals pty ltd - valganciclovir hydrochloride -
valganciclovir sandoz valganciclovir (as hydrochloride) 450 mg film coated tablet blister pack
sandoz pty ltd - valganciclovir, quantity: 450 mg - tablet, film coated - excipient ingredients: povidone; stearic acid; microcrystalline cellulose; crospovidone; titanium dioxide; hypromellose; polysorbate 80; iron oxide red; macrogol 400 - valganciclovir is indicated for the treatment of cytomegalovirus (cmv) retinitis in patients with acquired immunodeficiency syndrome (aids). valganciclovir is indicated for the prophylaxis of cmv infection and disease following solid organ transplantation in patients at risk of cmv disease.
ganciclovir injection, solution
exela pharma sciences, llc - ganciclovir (unii: p9g3ckz4p5) (ganciclovir - unii:p9g3ckz4p5) - ganciclovir 2 mg in 1 ml - ganciclovir injection is indicated for the treatment of cytomegalovirus (cmv) retinitis in immunocompromised adult patients, including patients with acquired immunodeficiency syndrome (aids) [see clinical studies (14)] . ganciclovir injection is indicated for the prevention of cmv disease in adult transplant recipients at risk for cmv disease [see clinical studies (14 )] . ganciclovir injection is contraindicated in patients who have experienced a clinically significant hypersensitivity reaction (e.g., anaphylaxis) to ganciclovir, valganciclovir or acyclovir. risk summary inanimal studies, ganciclovir caused maternal and fetal toxicity and embryo-fetal mortality in pregnant mice and rabbits as well as teratogenicity in rabbits at exposures two times the exposure at the recommended human dose (rhd) [see data] . although placental transfer of ganciclovir has been shown to occur based on ex vivo experiments with human placenta and on at least one case report in a pregnant woman, no adequate human data are a
highlights of prescribing information
leucadia pharmaceuticals - ganciclovir sodium (unii: 02l083w284) (ganciclovir - unii:p9g3ckz4p5) - ganciclovir for injection is indicated for the treatment of cytomegalovirus (cmv) retinitis in immunocompromised adult patients, including patients with acquired immunodeficiency syndrome (aids) [see clinical studies (14.1)] . ganciclovir for injection is indicated for the prevention of cmv disease in adult transplant recipients at risk for cmv disease [see clinical studies (14.2)]. ganciclovir for injection is contraindicated in patients who have experienced a clinically significant hypersensitivity reaction (e.g., anaphylaxis) to ganciclovir, valganciclovir, or any component of the formulation. risk summary in animal studies, ganciclovir caused maternal and fetal toxicity and embryo-fetal mortality in pregnant mice and rabbits as well as teratogenicity in rabbits at exposures two times the exposure at the recommended human dose (rhd) [see data] . although placental transfer
valganciclovir an valganciclovir (as hydrochloride) 450 mg film coated tablet bottle
juno pharmaceuticals pty ltd - valganciclovir hydrochloride -
valganciclovir 450 mg film-coated tablets
accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - valganciclovir - film-coated tablet - valganciclovir 450 mg - antivirals for systemic use